These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 20029401)

  • 1. Upgrading of Gleason score 6 prostate cancers on biopsy after prostatectomy in the low and intermediate tPSA range.
    Colleselli D; Pelzer AE; Steiner E; Ongarello S; Schaefer G; Bartsch G; Schwentner C
    Prostate Cancer Prostatic Dis; 2010 Jun; 13(2):182-5. PubMed ID: 20029401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and pathologic predictors of Gleason sum upgrading in patients after radical prostatectomy: results from a single institution series.
    Tilki D; Schlenker B; John M; Buchner A; Stanislaus P; Gratzke C; Karl A; Tan GY; Ergün S; Tewari AK; Stief CG; Seitz M; Reich O
    Urol Oncol; 2011; 29(5):508-14. PubMed ID: 19837614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer volume at biopsy predicts clinically significant upgrading.
    Dong F; Jones JS; Stephenson AJ; Magi-Galluzzi C; Reuther AM; Klein EA
    J Urol; 2008 Mar; 179(3):896-900; discussion 900. PubMed ID: 18207180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate biopsy clinical and pathological variables that predict significant grading changes in patients with intermediate and high grade prostate cancer.
    Moussa AS; Li J; Soriano M; Klein EA; Dong F; Jones JS
    BJU Int; 2009 Jan; 103(1):43-8. PubMed ID: 18782303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of primary Gleason pattern 4 in patients with Gleason score 7 tumours treated with radical prostatectomy.
    Khoddami SM; Shariat SF; Lotan Y; Saboorian H; McConnell JD; Sagalowsky AI; Roehrborn CG; Koeneman KS
    BJU Int; 2004 Jul; 94(1):42-6. PubMed ID: 15217428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate cancers scored as Gleason 6 on prostate biopsy are frequently Gleason 7 tumors at radical prostatectomy: implication on outcome.
    Pinthus JH; Witkos M; Fleshner NE; Sweet J; Evans A; Jewett MA; Krahn M; Alibhai S; Trachtenberg J
    J Urol; 2006 Sep; 176(3):979-84; discussion 984. PubMed ID: 16890675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
    Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
    J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathological features after radical prostatectomy in potential candidates for active monitoring.
    Griffin CR; Yu X; Loeb S; Desireddi VN; Han M; Graif T; Catalona WJ
    J Urol; 2007 Sep; 178(3 Pt 1):860-3; discussion 863. PubMed ID: 17631347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early detection of prostate cancer with low PSA cut-off values leads to significant stage migration in radical prostatectomy specimens.
    Berger AP; Spranger R; Kofler K; Steiner H; Bartsch G; Horninger W
    Prostate; 2003 Oct; 57(2):93-8. PubMed ID: 12949932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Over-diagnosis and under-diagnosis of screen- vs non-screen-detected prostate cancers with in men with prostate-specific antigen levels of 2.0-10.0 ng/mL.
    Pelzer AE; Colleselli D; Bektic J; Schaefer G; Ongarello S; Schwentner C; Aigner F; Mitterberger M; Steiner E; Bartsch G; Horninger W
    BJU Int; 2008 May; 101(10):1223-6. PubMed ID: 18190631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC
    Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathological features of Gleason score 6 prostate cancers in the low and intermediate range of prostate-specific antigen level: is there a difference?
    Pelzer AE; Colleselli D; Bektic J; Steiner E; Ramoner R; Mitterberger M; Schwentner C; Schaefer G; Ongarello S; Bartsch G; Horninger W
    BJU Int; 2008 Apr; 101(7):822-5. PubMed ID: 18261154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy: results from the Cancer of the Prostate Strategic Urologic Research Endeavor database.
    Grossfeld GD; Chang JJ; Broering JM; Li YP; Lubeck DP; Flanders SC; Carroll PR
    J Urol; 2001 Mar; 165(3):851-6. PubMed ID: 11176485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
    Kupelian P; Katcher J; Levin H; Zippe C; Klein E
    Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between upgrading of prostate biopsy and biochemical failure and unfavorable pathology after radical prostatectomy.
    Ozden C; Oztekin CV; Ugurlu O; Gokkaya S; Yaris M; Memis A
    Urol Int; 2009; 83(2):146-50. PubMed ID: 19752607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The proportion of free PSA and upgrading of biopsy Gleason score after radical prostatectomy.
    Visapää H; Hotakainen K; Lundin J; Ala-Opas M; Stenman UH
    Urol Int; 2010; 84(4):378-81. PubMed ID: 20299777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient risk stratification using Gleason score concordance and upgrading among men with prostate biopsy Gleason score 6 or 7.
    Serkin FB; Soderdahl DW; Cullen J; Chen Y; Hernandez J
    Urol Oncol; 2010; 28(3):302-7. PubMed ID: 19117774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The extent of biopsy involvement as an independent predictor of extraprostatic extension and surgical margin status in low risk prostate cancer: implications for treatment selection.
    Gao X; Mohideen N; Flanigan RC; Waters WB; Wojcik EM; Leman CR
    J Urol; 2000 Dec; 164(6):1982-6. PubMed ID: 11061896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gleason scores of prostate biopsy and radical prostatectomy specimens over the past 10 years: is there evidence for systematic upgrading?
    Smith EB; Frierson HF; Mills SE; Boyd JC; Theodorescu D
    Cancer; 2002 Apr; 94(8):2282-7. PubMed ID: 12001128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.